Contents
A revascularization question gives a coronary angiogram in words (left main stenosis, three-vessel disease, a diabetic patient, an ejection fraction) and asks what comes next: bypass surgery, a stent, or no procedure at all. Three facts usually decide it: is this an acute coronary syndrome or stable disease, how complex is the anatomy, and does the patient have diabetes or a low ejection fraction.
The revascularization algorithm
- Acute or stableSTEMI needs reperfusion now: primary PCI of the culprit artery. Stable ischemic heart disease starts with guideline-directed medical therapy; the question is whether a procedure adds survival or symptom relief.
- Left main diseaseSignificant left main stenosis: CABG is recommended to improve survival (class 1). PCI is a reasonable alternative in selected patients whose anatomy is of low to intermediate complexity (class 2a).
- Low ejection fractionMultivessel disease with LVEF of 35% or less: CABG improves survival (class 1), based mainly on the STICH extension.
- DiabetesMultivessel disease in a patient with diabetes who can have surgery: CABG with a left internal mammary artery graft to the LAD is preferred over PCI (class 1), based on FREEDOM. PCI is an option for poor surgical candidates.
- Anatomic complexityComplex multivessel disease (SYNTAX score above 33): CABG is reasonable for a survival benefit over PCI. With less complex anatomy, CABG and PCI give similar results, and the heart team decides with the patient.
- Normal ejection fraction, no diabetes, no left mainRevascularization for survival is only class 2b in three-vessel disease with normal LVEF. It can reduce cardiac death, spontaneous MI and urgent revascularization (class 2a), and it relieves angina that persists on medical therapy.
- One or two vessels, LAD spared, normal LVEFPCI to improve survival is not recommended (class 3). Treat medically and revascularize for symptoms.
The 2021 downgrade for three-vessel disease with normal LVEF was driven largely by the ISCHEMIA trial and remains disputed: the cardiac surgery societies (STS and AATS) did not endorse that recommendation, arguing that ISCHEMIA was weighted too heavily. Exam questions follow the guideline.
The trials behind the answers
| Trial | Population | Result | What it changed |
|---|---|---|---|
| FREEDOM (2012) | Diabetes with multivessel CAD | CABG lowered the combined rate of death, MI and stroke compared with drug-eluting stents, with more strokes after CABG | CABG is preferred in diabetic multivessel disease |
| STICH extension (2016) | Ischemic cardiomyopathy, LVEF 35% or less | CABG plus medical therapy lowered 10-year all-cause mortality compared with medical therapy alone | CABG for multivessel disease with low LVEF |
| ISCHEMIA (2020) | Stable CAD with moderate or severe ischemia, excluding left main disease and LVEF below 35% | An initial invasive strategy did not reduce ischemic events or death over a median of 3.2 years; angina improved | Medical therapy first for most stable patients |
| CULPRIT-SHOCK (2017) | Acute MI with cardiogenic shock and multivessel disease | Culprit-only PCI did better than immediate multivessel PCI | Routine non-culprit PCI in shock is harmful |
Acute coronary syndromes
- STEMI: primary PCI of the culprit artery. If PCI cannot be done within 120 minutes, a fibrinolytic within 30 minutes, then transfer.
- STEMI with multivessel disease, hemodynamically stable: PCI of significant non-culprit lesions (complete revascularization), at the index procedure or staged, reduces cardiovascular death or MI.
- STEMI with cardiogenic shock: PCI of the culprit artery only. Routine PCI of non-culprit arteries at the same time is harmful (class 3).
- NSTE-ACS: invasive angiography; the same anatomy rules then apply. Left main or complex multivessel disease, especially with diabetes, points to CABG.
Clue in the stem, next best step
| Clue in the stem | What it points to | Next best step |
|---|---|---|
| Stable angina, 80% left main stenosis, good surgical candidate | Left main disease | CABG |
| Type 2 diabetes, three-vessel disease including the proximal LAD | Diabetic multivessel disease | CABG with a LIMA graft to the LAD |
| Ischemic cardiomyopathy, LVEF 30%, multivessel disease | Low ejection fraction | CABG plus guideline-directed medical therapy |
| Single-vessel right coronary disease, normal LVEF, mild angina on one drug | Low-risk stable disease | Optimize medical therapy; PCI only for persistent symptoms |
| Inferior STEMI, transfer time to a PCI center 3 hours | PCI not available in time | Fibrinolysis within 30 minutes, then transfer |
| Anterior STEMI with shock, two other diseased arteries | Cardiogenic shock with multivessel disease | Culprit-only PCI |
| Stable STEMI patient after culprit PCI, 80% stenosis in another artery | Non-culprit disease | Staged or same-procedure PCI of that lesion |
Where students lose points
- Stenting multivessel disease in a patient with diabetes who can have surgery. CABG is preferred.
- Sending every stable patient with a positive stress test to angiography. Medical therapy comes first unless the anatomy or ejection fraction changes the survival picture.
- Stenting every narrowed artery during primary PCI in cardiogenic shock.
- Forgetting the LIMA graft to the LAD, the part of CABG that carries its long-term benefit.
- Answering PCI for left main disease in a good surgical candidate with complex anatomy.
Practice question
A 61-year-old man with type 2 diabetes and hypertension has exertional chest pressure that has persisted for 4 months despite metoprolol, isosorbide mononitrate, aspirin and atorvastatin. HbA1c is 7.9%. A stress test showed a large area of anterior and lateral ischemia. Coronary angiography shows 85% stenosis of the proximal left anterior descending artery, 80% stenosis of the left circumflex artery and 75% stenosis of the right coronary artery; the left main is normal. Left ventricular ejection fraction is 50%. He has no other major illnesses and is a good surgical candidate.
Which of the following is the most appropriate management?
- Continue medical therapy alone
- PCI of the left anterior descending artery only
- Multivessel PCI with drug-eluting stents
- CABG with a left internal mammary artery graft to the LAD
- Fibrinolytic therapy
Show the answer
Answer: D. He has diabetes, three-vessel disease involving the proximal LAD and angina that persists on medical therapy, and he can have surgery. CABG with a LIMA graft to the LAD is recommended over PCI in this group to reduce death and repeat revascularization, based on FREEDOM.
Why the others are wrong. A: his angina persists despite good medical therapy, and his anatomy carries a survival argument for CABG. B: incomplete revascularization leaves two diseased arteries. C: multivessel PCI is the option for diabetic patients who are poor surgical candidates. E: fibrinolysis is for STEMI when PCI is not available in time, not for stable disease.
60-second recall
Say each answer out loud before you reveal it, then mark yourself. Retrieval, not rereading, is what makes it stick.
1Left main disease
CABG (class 1); PCI in selected low-complexity anatomy (class 2a).Did you get it?2Diabetes with multivessel disease
CABG with LIMA to LAD (FREEDOM).Did you get it?3Multivessel disease with LVEF 35% or less
CABG (STICH extension).Did you get it?4Three-vessel disease with normal LVEF
Survival benefit only class 2b (ISCHEMIA).Did you get it?5STEMI with shock
Culprit-only PCI.Did you get it?6Stable STEMI with multivessel disease
Complete revascularization.Did you get it?
Make retrieval a habit on every topic with Learning to Learn Medicine. Module 1 is free; the full bundle (the course plus all 12 Recall Labs) is a one-time $199.
Next: browse every Board Review post, review anticoagulants vs antiplatelets vs thrombolytics, or see MedRise for students.
Sources
- Lawton JS, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. Circulation, 2022 (PubMed 34882435)
- American College of Cardiology. Key takeaways from the 2021 coronary revascularization guidelines, 2022
- Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. Circulation, 2025 (PubMed 40014670)
- Farkouh ME, et al. Strategies for multivessel revascularization in patients with diabetes (FREEDOM). N Engl J Med, 2012 (PubMed 23121323)
- Velazquez EJ, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy (STICH extension). N Engl J Med, 2016 (PubMed 27040723)
- Maron DJ, et al. Initial invasive or conservative strategy for stable coronary disease (ISCHEMIA). N Engl J Med, 2020 (PubMed 32227755)
- Thiele H, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock (CULPRIT-SHOCK). N Engl J Med, 2017 (PubMed 29083953)
MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.



